Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Deciphera Pharmaceuticals reports robust Q4 performance and eyes market expansion

Deciphera Pharmaceuticals delivered strong financial results and outlined strategic priorities for future growth.
The company's focus on ctDNA analysis, market expansion, and potential label expansions position them well for continued success.
While facing uncertainties in guideline updates and market competition, Deciphera Pharmaceuticals remains optimistic about growth opportunities.

Deciphera Pharmaceuticals excels in Q1 2023, eyes international expansion

Deciphera Pharmaceuticals demonstrates strong financial performance and strategic achievements in Q1 2023, positioning the company for continued growth and market success.
While facing challenges from market dynamics and competition, the company's focus on international expansion, new drug development, and commercialization efforts presents promising opportunities.
By leveraging strengths in reimbursement ratings, clinical significance of key drugs, and pre-commercial activities, Deciphera is poised to capitalize on market opportunities and drive future growth.

Deciphera Pharmaceuticals excels in Q2, eyes international growth and innovation

Deciphera Pharmaceuticals delivered a standout performance in Q2 2023, driven by QINLOCK's robust revenue generation and international expansion.
While facing challenges such as high operating expenses and clinical trial complexities, the company remains focused on patient outcomes and program advancements.
Opportunities lie in continued revenue growth, clinical program progress, and leadership transitions, positioning Deciphera for future success and innovation.

Deciphera Pharmaceuticals excels in Q3 with record sales and innovative pipeline

Deciphera Pharmaceuticals shows strong financial and clinical performance in Q3 2023.
Balancing successful study outcomes with potential regulatory challenges and patient dynamics.
Company poised for significant revenue growth and market expansion with innovative products.
Continued focus on commercial success and pipeline advancement to drive future growth.

Deciphera Pharmaceuticals reports robust Q4 performance and eyes global expansion

Deciphera Pharmaceuticals showcased strong financial performance, clinical advancements, and strategic plans for growth in Q4 2023, positioning the company for continued success.
While facing challenges in market differentiation and operational execution, the company has opportunities for market expansion, record sales, and clinical development milestones in 2024.
Overall, Deciphera Pharmaceuticals' focus on QINLOCK sales, vimseltinib development, and international expansion underscores a comprehensive growth strategy and potential for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.

Investors have run back to the stock after promising clinical results.

Deciphera Pharmaceuticals: Buy at the High?

Deciphera Pharmaceuticals continued a two-day sprint Wednesday on excitement over a stomach cancer treatment, but at least one analyst far prefers rival biotech company Blueprint Medicines.
The post This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival appeared first on Investor's Business Daily.

This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival

Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free  survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.

Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%

Best Buy

Genworth Financial

Good news on the trade front was instrumental in lifting many stocks on Tuesday.

Why Best Buy, Deciphera Pharmaceuticals, and Genworth Financial Jumped Today

Solid clinical results were just what the struggling pharma company needed.

Here's Why Deciphera Pharmaceuticals Rose as Much as 115% Today

Deciphera Pharmaceuticals stock nearly doubled Tuesday after the biotech company said its stomach cancer treatment benefited patients who've exhausted at least three other options.
The post This Biotech Stock Rocketed 85% In Bullish Volume On A Cancer Drug appeared first on Investor's Business Daily.

This Biotech Stock Rocketed 85% In Bullish Volume On A Cancer Drug

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) shares nearly doubled on Tuesday after the firm announced top-line results from its late-stage trial treating patients with gastrointestinal stromal tumors (GIST).

Breakthrough Gastrointestinal Tumor Therapy Reaches New Milestone

Shares of thinly traded small-cap biotech Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) are skyrocketing Tuesday morning following a couple of clinical readouts from the company.

Deciphera Soars On Positive Readouts For Gastrointestinal Tumor Drug

Shares of Deciphera Pharmaceuticals Inc. DCPH, +124.46% more than doubled toward a 14-month high in active premarket trading Tuesday

Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data

Investors need to pay close attention to Deciphera (DCPH) stock based on the movements in the options market lately.

Implied Volatility Surging for Deciphera (DCPH) Stock Options

Deciphera Pharmaceuticals (DCPH) needs investors to pay close attention to the stock based on moves in the options market lately.

Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock

News for Deciphera Pharmaceuticals Stock (DCPH)